Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ECE1 | P42892 | 2/20 | 0.55 |
| ▸ | KISS1R | Q969F8 | 6/20 | 0.52 |
| ▸ | ACE | P12821 | 2/20 | 0.51 |
| ▸ | GHSR | Q92847 | 1/20 | 0.51 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22198557 | 0.97 | ECE1 (0.54) | ECE1KISS1RACEGHSRALOX15 | |
| SCHEMBL21915908 | 0.97 | ECE1 (0.54) | ECE1KISS1RACEGHSRALOX15 | |
| SCHEMBL20793358 | 0.97 | ECE1 (0.54) | ECE1KISS1RACEGHSRALOX15 | |
| SCHEMBL22799935 | 0.91 | ECE1 (0.54) | ECE1KISS1RACEGHSR | |
| SCHEMBL20385815 | 0.90 | ECE1 (0.53) | ECE1KISS1RACEGHSR | |
| SCHEMBL20385916 | 0.90 | ECE1 (0.53) | ECE1KISS1RACEGHSR | |
| SCHEMBL20385839 | 0.90 | ECE1 (0.53) | ECE1KISS1RACEGHSR | |
| SCHEMBL20385886 | 0.90 | ECE1 (0.53) | ECE1KISS1RACEGHSR | |
| SCHEMBL21915900 | 0.90 | ECE1 (0.55) | ECE1KISS1RACEGHSR | |
| SCHEMBL22198554 | 0.90 | KISS1R (0.54) | ECE1KISS1RACEGHSR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4306524-A2 | LYMPHATIC SYSTEM-DIRECTING LIPID PRODRUGS | PureTech LYT, Inc. (US) | 2024-01-17 | — | — | EP | disclosed |
| US-20220143038-A1 | LIPID PRODRUGS OF MYCOPHENOLIC ACID AND USES THEREOF | PURETECH LYT, INC. (US) | 2022-05-12 | — | — | US | disclosed |
| US-20220125933-A1 | LIPID PRODRUGS OF JAK INHIBITORS AND USES THEREOF | SEAPORT THERAPEUTICS, INC. | 2022-04-28 | — | — | US | disclosed |
| WO-2021159021-A1 | LIPID PRODRUGS OF NEUROSTEROIDS | PURETECH LYT, INC. (US) | 2021-08-12 | — | — | WO | disclosed |
| WO-2021051172-A1 | LIPID PRODRUGS OF CELECOXIB AND USES THEREOF | MONASH UNIVERSITY (AU) | 2021-03-25 | — | — | WO | disclosed |
| WO-2020028787-A1 | LIPID PRODRUGS OF PREGNANE NEUROSTEROIDS AND USES THEREOF | PureTech Health LLC (US) | 2020-02-06 | — | — | WO | disclosed |
| WO-2019046491-A1 | LYMPHATIC SYSTEM-DIRECTING LIPID PRODRUGS | ARIYA THERAPEUTICS, INC. (US) | 2019-03-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220125933-A1 | LIPID PRODRUGS OF JAK INHIBITORS AND USES THEREOF | JAK1, JAK2, JAK3 | ECE1 3180/4885KISS1R 2302/4885ACE 2083/4885 |
| US-20220143038-A1 | LIPID PRODRUGS OF MYCOPHENOLIC ACID AND USES THEREOF | MALT1, CYP2B6, LIPA | ECE1 3456/4885KISS1R 3572/4885ACE 906/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.